2nd Circ. Revives NewLink Investor Suit Over Cancer Drug
The Second Circuit on Monday revived a proposed class action that accuses NewLink Genetics Corp. executives of making misrepresentations while touting the biopharma company's pancreatic cancer treatment....To view the full article, register now.
Already a subscriber? Click here to view full article